Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds
– Invests in 100th Portfolio Company, Celebrates 25th Year of Franchise Operation,
– Announces Promotion of Lauren Flickinger and Ben Scruggs, Ph.D., as Partners,
DURHAM, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hatteras Venture Partners announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I) with over $200 million in capital commitments from limited partners. The fund closings come at a time as Hatteras has invested in its 100th portfolio company and marks 25 years of building transformational human medicine companies that benefit patients and the professionals who serve them.
"Last week, our portfolio company, HistoSonics, announced its strategic acquisition in a landmark transaction. Across 100 portfolio companies and 25 years, we've had our share of exhilarating wins like this, along with heartbreaking disappointments," said Clay Thorp, General Partner of Hatteras Venture Partners. "What has been most gratifying in this journey is the relationships we have made with scholarly innovators, committed entrepreneurs, and resilient co-investors. We look forward to continuing to invest in transformative life sciences companies disrupting the status quo in healthcare and accelerating the pace of innovation."
Track Record of Success
Hatteras began in 2000 with the closing of Hatteras Venture Partners I, LP, a seed-stage venture fund with $2.93 million in capital. Today, the firm manages over $900 million in capital focused on seed- and early-stage companies in the health innovation sectors of biotechnology, medtech, and healthtech.
Across HVP I to HVP VII, the following are highlights of several of the exciting companies Hatteras has been a part of:
HistoSonics, Inc. pioneered the development of histotripsy, a completely new modality for tissue destruction using ultrasound. Its Edison® Histotripsy System was FDA approved in October 2023 for the destruction of liver tumors. Since then, the company has seen a highly successful ...
